ChemT Biotechnology
ChemT Biotechnology is an AI biotech company headquartered in Singapore with operations in the US, building CelMo, an AI-driven "virtual cell" platform trained on billions to trillions of proprietary biological sequencing reads and validated in the lab.
Position in SVTR
Snapshot 2026-10-28- Startup SignalsTop 25%new
- Life SciencesTop 25%
- AI for ScienceTop 25%
- Drug DiscoveryTop 25%
About
ChemT Biotechnology is an AI biotech company headquartered in Singapore with operations in the US, building CelMo, an AI-driven "virtual cell" platform trained on billions to trillions of proprietary biological sequencing reads and validated in the lab. The platform identifies cell pathways to improve manufacturing performance, designs small molecules to guide cell behavior, and supports AI-assisted cell engineering for pharmaceutical, biotech, and CDMO customers; the company has commercial partnerships with 40+ global customers.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 5
Founders / team· 3
Funding history
- 2026-06-23Seed$4M
Investors · Wavemaker Ventures, SEEDS Capital, Wavemaker 360 Health, Draper University Ventures, Temasek Life Sciences AcceleratorSource · technode.global ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- ChemT Biotechnology
CelMo AI virtual cell platform helping biopharma/CDMO companies improve cell culture and antibody production efficiency
Seed · $5M · 2026-06
$5M
United States
BusinessLatest roundTotal raisedDate- Onepot
Small-molecule synthesis for drug discovery for biopharma companies (AI + automated synthesis)
Seed · $13M · 2025-11
$13M - Cheiron
AI-native "drug program operating system" for biopharma teams that models drug R&D programs on a life sciences knowledge graph
Seed · $8M · 2026-07
$8M - Argon AI
Digital collaboration platform with integrated AI tools for biopharma teams to manage research projects and data
Seed · $6M · 2025-07
$6M
China
BusinessLatest roundTotal raisedDate- 元示科技
AI Virtual Cell (AIVC): a raw biological data engine and general-purpose cell foundation model forming a life sciences base, with an ultra-high-throughput cell perturbation platform to predict drug perturbation effects across cell types, for early-stage drug discovery at pharmaceutical companies and research institutions.
Angel · 2026-10
— - ATLATL Innovation Center
R&D infrastructure and incubation for early-stage biopharma: shared labs, resident scientists and project management, GMP process optimization, preclinical pharmacology and toxicology, plus an AI drug screening module, for biopharma startups, university and institute spinout teams and multinational pharma
— - 华源智因
AI virtual cell models for predicting drug efficacy in humans
Seed · 2026-07
—
Europe
BusinessLatest roundTotal raisedDate- kyron.bio
Develops a precision biotech platform for engineering glycans to improve drug efficacy and safety
Seed · $6M · 2025-05
$6M - Rivercell
In-house automated wet lab generating large-scale single-cell perturbation data to train "AI virtual cell" models that predict human cell responses to drugs and genetic changes
Seed · 2026-10
— - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Mithril Medicine
Antibody drug development for rare muscular dystrophies, using AI agents to coordinate outsourced labs.
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Related coverage
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 11 at a nearby stage
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.